{"id":412227,"date":"2021-01-11T10:59:43","date_gmt":"2021-01-11T15:59:43","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412227"},"modified":"2021-01-11T10:59:43","modified_gmt":"2021-01-11T15:59:43","slug":"delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","title":{"rendered":"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Jan.  11, 2021  (GLOBE NEWSWIRE) &#8212; Delcath Systems, Inc. (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oCM301HInYFCHx_3DZCySf8qZSRhweA537UFe9U-f6AN-AaYduaJghq5-cllo6F0qKhlYV2d7V8uzHNYryuGkkJrJIVmOJrr2UPX9ZF6DF6u1LfCJEFPerguMZvoxc9D6vFzRmTXx9bui-gA8uvE_4F4DUjFf6Rx1wVMRG7YxljAnE0qqpGRyPz533wNS7Ao\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>DCTH<\/u><\/strong><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=glI-ba5GecO75cl1tVz1g9iaDBkzg5LSRla_KgdR9xFnPey3_pz4XEa2x4jLZK9QL6XYfsorhdc209rXuc_Bdmus6vCKheW0RJTY5pDl1CMCMpbT70TTDH3E8aY-9OHUmOHOl82fnE6iAp9vDn_IN9bBt2Ls6A143QELm55oYYyyUWl9vCpMI3UfTlqGJQUR\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>\u00a0<\/strong><\/a>), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.<\/p>\n<p>The presentation is now available \u201con-demand\u201d by visiting https:\/\/hcwevents.com\/bioconnect\/#<\/p>\n<p>\n        <strong>About Delcath Systems, Inc.<\/strong>\n      <\/p>\n<p>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection\/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food &amp; Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT\u00ae Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.<\/p>\n<p>\n        <strong>Safe Harbor \/ Forward-Looking Statements<\/strong>\n      <\/p>\n<p>The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company\u2019s\u00a0clinical trials, including without limitation the mOM and ICC clinical trial programs, our determination whether to continue the ICC clinical trial program or to focus on other alternative indications, and timely monitoring and treatment of patients in the global Phase 3 mOM clinical trial and the impact of the COVID-19 pandemic on the completion of our clinical trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; approval of Individual Funding Requests for reimbursement of the CHEMOSAT product; the impact, if any, of ZE reimbursement on potential CHEMOSAT product use and sales in\u00a0Germany; clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK; the Company\u2019s ability to successfully commercialize the HEPZATO KIT\/CHEMOSAT system and the potential of the HEPZATO KIT\/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver; our ability to obtain reimbursement for the CHEMOSAT system in various markets; approval of the current or future HEPZATO KIT\/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and\/or in foreign markets; actions by the FDA or foreign regulatory agencies; the Company\u2019s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same; uncertainties relating to the timing and results of research and development projects; and uncertainties regarding the Company\u2019s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the\u00a0Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>\n        <em>Delcath Investor Relations<\/em>\n      <\/p>\n<p>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uGqYNbNIUSia0K-urQG0E0rXEGwFxHERCjiGpGQhS14fu9VONwsdA_QDKZkNOF69SoXQxcoe3kRmcjxUFdJ53x1F343KnrUbW_Ttk2vTlC5YaEz1hnUyRaN4LzqiCYL_jTjKtmDPSXzjpWPPanpnv7tpJsreKAbnjtZQ3Gb3al4vtt_nheAewJ_74RCwsSOOXrIMxe1btKqbMQFun4bEOu0-UwHlVp_cVTP_tCUK2cQ8wg3ICHbmP3d7MnTFTWMzWUrJLmtuNBs-xbw9Ng6OG3FAuxFJsfbMeeTUT-RE68M=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>investorrelations@delcath.com<\/u><\/strong><\/a><\/p>\n<p>\n        <em>Hayden IR<\/em>\n      <\/p>\n<p>James Carbonara\u00a0<br \/>(646)-755-7412\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X96w3Wp_sk_MWki_eGm8qYmpENJK5XU0F95atgSt75KQ157t7-ZCRplx6u-KDTqI1FrWJYBzeYxtMKSwKd6lVz-nafXOUurNK0jfLpMCdD8fkqSz2bjnfKqaT5zNXshkj2N8naE6FKb8byhFjTcWoG-St0-eZmH8lCzeaP8ZukgfkjrAuI1TvuJf1zpIql2lNLfXdx14oFSN0LWJCSJ9R1T3UW4kSSIK8a25aGJQ8dT7RdhaULGJeru8jaUq3vkdQ4A8UWAmSRy1HmcO_QrfefNQLY4BMRVIulzBHY1CvqaVORybQtEHRwKH0x3xgv0r7RIwmds12fU9TV7H2llrkfCb0FyXjGpVy6FmNmLnS_G4BUwMNaqdNOPd2cVX8Jf4cw7xMkinS6Cm_MeHz5uEzM0zDisRklGFztwH6rOOpQ7s_ddOShUJ6W6nNq7wuoGZkMMaapxeOEikRoS1zPrggQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>james@haydenir.com<\/u><\/strong><\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/906c1be2-f735-465d-8023-72b4126c4050\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Delcath Systems, Inc. (Nasdaq:\u00a0DCTH\u00a0), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The presentation is now available \u201con-demand\u201d by visiting https:\/\/hcwevents.com\/bioconnect\/# About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection\/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food &amp; Drug Administration (FDA) for sale in the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412227","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Delcath Systems, Inc. (Nasdaq:\u00a0DCTH\u00a0), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The presentation is now available \u201con-demand\u201d by visiting https:\/\/hcwevents.com\/bioconnect\/# About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection\/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food &amp; Drug Administration (FDA) for sale in the &hellip; Continue reading &quot;Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T15:59:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference\",\"datePublished\":\"2021-01-11T15:59:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"wordCount\":640,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"name\":\"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=\",\"datePublished\":\"2021-01-11T15:59:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_locale":"en_US","og_type":"article","og_title":"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","og_description":"NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Delcath Systems, Inc. (Nasdaq:\u00a0DCTH\u00a0), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The presentation is now available \u201con-demand\u201d by visiting https:\/\/hcwevents.com\/bioconnect\/# About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection\/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food &amp; Drug Administration (FDA) for sale in the &hellip; Continue reading \"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T15:59:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference","datePublished":"2021-01-11T15:59:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"wordCount":640,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","name":"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=","datePublished":"2021-01-11T15:59:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc1NyMzOTEzMjM4IzIwMTA1ODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/delcath-systems-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412227"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}